Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, issued approximately 3.9 million shares of common stock at a purchase price of $7.50 per share in a registered direct offering priced at-the-market under Nasdaq rules.
H.C. Wainwright was exclusive placement agent for the offering.
The gross proceeds from the offering are expected to be approximately $29 million before deducting placement agent fees and other offering expenses. Enochian currently intends to use the net proceeds from the offering for working capital and general corporate purposes. Read more.
